The Board has not set a timetable to complete the strategic review process nor have any decisions been made relating to strategic alternatives at this time. There is also no assurance that this process will result in any specific transaction, including a business combination or disposition of the Company or any of its assets. The Company does not plan to make further comment or disclosures regarding this review until such time as required by law or otherwise deemed appropriate.
About Highmark
Highmark was created to change the paradigm of testing and management for brain and mental health. Highmark's approach is focused on providing real-time data to health providers to support proactive, preventative interventions and targeted care planning to improve health outcomes.
Highmark offers the world's first gamified, FDA cleared patient-led assessments as well as digital clinician-led assessments of neurofunction and balance.
To date the Highmark team has enjoyed significant success in the software as a medical device marketplace of
In addition to the US RPM marketplace, Highmark has continued to explore other relevant markets for its EQ suite, notably the field of Chronic Disease monitoring where it is going to be used to attempt to define biomarkers of brain injury in dialysis patients. Highmark is currently working with a large global Dialysis company in a study where the Highmark software will define digital biomarkers of brain injury associated with dialysis. The intent of the collaboration is so that the defined biomarkers can then be utilized to improve the methods and techniques of hemodialysis.
The Highmark team has also developed software used by the
By unlocking insights, Highmark's platform enables precision medicine and creates a more contemporary model for delivering better outcomes in medical, mental health and rehabilitation services.
For further information:
sanjeev@highmark.tech or 1-855-969-5079
Investor Relations
ir@highmark.tech
Source:
2023 GlobeNewswire, Inc., source